Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) up 0.1%.
Arcellx (ACLX) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.
Agios Pharmaceuticals (AGIO) shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.
Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。